Brain, Vol. 117, No. 3, 501-507, 1994
© 1994 Guarantors of Brain
research-article |
Clinical observations on the rate of progression of idiopathic parkinsonism
Neurodegenerative Disorders Centre, Division of Neurology, Department of Medicine, Vancouver Hospital and Health Sciences Centre, University of British Columbia Canada
Correspondence to:
Correspondence to: Dr D. B. Calne, Neurodegenerative Disorders Centre, Vancouver Hospital and Health Sciences Centre, Purdy Pavilion, 2211 Wesbrook Mall, Vancouver, BC, Canada V6T 2B5
The time course of evolution of clinical deficits has been a traditional guide to the nature of the aetiopathogenesis of neurological disease. We studied the influence of ageing and duration of disease on the natural history of idiopathic parkinsonism (IP). Two hundred and thirty-eight patients with IP were examined while off medication. Bradykinesia scores were analysed against patients' age and duration of disease by multiple regression. There was no significant interaction between the effects of age and of duration (P = 0.923). We conclude that age and duration of symptoms influence the natural history of IP additively and independently. Furthermore, the rate of neuronal death is more rapid in the earlier stages of evolution of the pathology; subsequently, the velocity of progression slows down to approach the rate of attrition produced by normal ageing. This time course has implications for possible models of pathogenesis.
Parkinson's disease; natural history; pathogenesis; ageing
.
Received June 29, 1993. Revised January 24, 1994. Accepted February 8, 1994.
*Present address: Oregon Health Sciences University, 3181 SW Sam Jackson Park Road, L226 Portland, Oregon 97201-3098, USA
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. Nandhagopal, L. Kuramoto, M. Schulzer, E. Mak, J. Cragg, C. S. Lee, J. McKenzie, S. McCormick, A. Samii, A. Troiano, et al. Longitudinal progression of sporadic Parkinson's disease: a multi-tracer positron emission tomography study Brain, November 1, 2009; 132(11): 2970 - 2979. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Levy The Relationship of Parkinson Disease With Aging Arch Neurol, September 1, 2007; 64(9): 1242 - 1246. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Kempster, D. R. Williams, M. Selikhova, J. Holton, T. Revesz, and A. J. Lees Patterns of levodopa response in Parkinson's disease: a clinico-pathological study Brain, August 1, 2007; 130(8): 2123 - 2128. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Wider, H. Russmann, J.-G. Villemure, B. Robert, J. Bogousslavsky, P. R. Burkhard, and F. J. G. Vingerhoets Long-duration response to levodopa in patients with advanced Parkinson disease treated with subthalamic deep brain stimulation. Arch Neurol, July 1, 2006; 63(7): 951 - 955. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Poewe The need for neuroprotective therapies in Parkinson's disease: A clinical perspective Neurology, May 23, 2006; 66(10_suppl_4): S2 - S9. [Abstract] [Full Text]
|
|
|
|
|
|
G. Levy, E. D. Louis, L. Cote, M. Perez, H. Mejia-Santana, H. Andrews, J. Harris, C. Waters, B. Ford, S. Frucht, et al. Contribution of Aging to the Severity of Different Motor Signs in Parkinson Disease Arch Neurol, March 1, 2005; 62(3): 467 - 472. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. S. Lee, M. Schulzer, R. de la Fuente-Fernandez, E. Mak, L. Kuramoto, V. Sossi, T. J. Ruth, D. B. Calne, and A. J. Stoessl Lack of Regional Selectivity During the Progression of Parkinson Disease: Implications for Pathogenesis Arch Neurol, December 1, 2004; 61(12): 1920 - 1925. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Russmann, J. Ghika, J.-G. Villemure, B. Robert, J. Bogousslavsky, P. R. Burkhard, and F. J.G. Vingerhoets Subthalamic nucleus deep brain stimulation in Parkinson disease patients over age 70 years Neurology, November 23, 2004; 63(10): 1952 - 1954. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. C. Koller, K. E. Lyons, and W. Truly Effect of levodopa treatment for parkinsonism in welders: A double-blind study Neurology, March 9, 2004; 62(5): 730 - 733. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Marek, D. Jennings, and J. Seibyl Imaging the dopamine system to assess disease-modifying drugs: Studies comparing dopamine agonists and levodopa Neurology, September 23, 2003; 61(90063): S43 - 48. [Full Text]
|
|
|
|
|
|
F. J.G. Vingerhoets, J.-G. Villemure, P. Temperli, C. Pollo, E. Pralong, and J. Ghika Subthalamic DBS replaces levodopa in Parkinson's disease: Two-year follow-up Neurology, February 12, 2002; 58(3): 396 - 401. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Jankovic and A. S. Kapadia Functional Decline in Parkinson Disease Arch Neurol, October 1, 2001; 58(10): 1611 - 1615. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. K. Morrish, P. Vieregge, J. Hagenah, I. Heberlein, C. Klein, and H.-P. Ludin Parkinson's disease in twins Neurology, April 25, 2000; 54(8): 1710 - 1711. [Full Text] [PDF]
|
|
|
|
 |
|
 M. A Hely, J. G L Morris, R. Traficante, W. G J Reid, D. J O'Sullivan, and P. M Williamson The Sydney multicentre study of Parkinson's disease: progression and mortality at 10 years J. Neurol. Neurosurg. Psychiatry, September 1, 1999; 67(3): 300 - 307. [Abstract] [Full Text]
|
|
|
|
|
|
W. C. Koller, J. T. Hutton, E. Tolosa, and R. Capilldeo Immediate-release and controlled-release carbidopa/levodopa in PD : A 5-year randomized multicenter study Neurology, September 1, 1999; 53(5): 1012 - 1012. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. D. Louis, M. X. Tang, L. Cote, B. Alfaro, H. Mejia, and K. Marder Progression of Parkinsonian Signs in Parkinson Disease Arch Neurol, March 1, 1999; 56(3): 334 - 337. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. de Rijk, M. M. B. Breteler, J. H. den Breeijen, L. J. Launer, D. E. Grobbee, F. G. A. van der Meche, and A. Hofman Dietary Antioxidants and Parkinson Disease: The Rotterdam Study Arch Neurol, June 1, 1997; 54(6): 762 - 765. [Abstract] [PDF]
|
|